z-logo
Premium
Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts *
Author(s) -
De Lazzari E,
León A,
Arnaiz JA,
Martinez E,
Knobel H,
Negredo E,
Clotet B,
Montaner J,
Storfer S,
Asenjo MA,
Mallolas J,
Miró JM,
Gatell JM
Publication year - 2008
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/j.1468-1293.2008.00552.x
Subject(s) - nevirapine , medicine , confidence interval , hazard ratio , odds ratio , antiretroviral therapy , rash , clinical endpoint , gastroenterology , randomized controlled trial , human immunodeficiency virus (hiv) , immunology , viral load
Objectives A warning advising a higher risk of hepatotoxicity in antiretroviral‐naive patients starting a nevirapine‐containing combination antiretroviral therapy (NcART) has been issued by health authorities. It is unclear whether this higher risk also applies to stable virologically suppressed patients starting NcART. Methods We performed a meta‐analysis of published randomized studies including virologically suppressed patients who switched to NcART with a follow‐up ≥3 months. CD4 cell cell counts were classified as high (HCD4) (400 cells/μL for males and 250 cells/μL for females) or low (LCD4). The main endpoint was hepatotoxicity within the first 3 months. Results Four studies with a pooled total of 410 patients were included. The risk of hepatotoxicity within the first 3 months was 2% and 4% in the LCD4 and HCD4 groups, respectively, with a combined odds ratio of 1.46 [95% confidence interval (CI) 0.43–4.98; P =0.54]. The risk of hepatotoxicity at any point during the study was similar in both groups, with a combined hazard ratio of 0.8 (95% CI 0.3–2.5; P =0.80). Conclusions In our study, virologically suppressed patients switching to nevirapine did not have a significantly higher risk of hepatotoxicity or rash when stratified by gender and CD4 cell count, although small differences may have gone undetected because of the sample size limitation.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here